01 · THE LEAD COMPOUND
BPC-157: Research Overview
A pentadecapeptide with a large reputation and a small human dataset. Almost everything known about it comes from rats — including everything that gets described as nerve repair.
The honest summary
BPC-157 is a lab-made chain of fifteen amino acids, copied from part of a protein found in stomach juice. In animals it appears to help injured tissue rebuild, and the effect most consistently traced in those animals is the growth of new small blood vessels [4].
The honest headline is about who was studied. Almost all of this research was done in rats. A 2025 review of the literature counted only three small pilot studies in people and said large, careful human trials are still missing [2]. One of those pilots gave the peptide by drip to two healthy adults and reported no problems [1] — two people is a safety signal, not proof that anything works.
On nerves specifically, the record is thinner still. There is no study here in which a damaged nerve in a person, or even in an animal's arm or leg, was watched regrowing under BPC-157. What exists is a review of rat brain and gut work [7]. That is the whole neural case, and this page keeps saying so.
What it is
BPC-157 is a synthetic fifteen-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and the molecular formula C62H98N16O22. The sequence is drawn from a partial region of a human gastric juice protein known as Body Protection Compound, which is where the name comes from. In the older literature it also appears as PL 14736, PLD-116 and PL-10.
Its pharmacokinetics were characterised formally only in 2022, in rats and beagle dogs [3]. That work found linear kinetics, an elimination half-life under thirty minutes, intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, excretion by urine and bile, and rapid breakdown into small peptide fragments that enter ordinary amino-acid metabolism.
Two things follow, and both matter for any neural claim. First, no equivalent human pharmacokinetic dataset exists, so how much intact peptide reaches any particular tissue in a person is unmeasured. Second, a half-life under half an hour means the compound is present only briefly, which makes any account of sustained tissue effects depend on downstream signalling rather than on the molecule lingering.
How it is said to work
The best-characterised mechanism is angiogenesis — the formation of new blood vessels. A 2017 study reported that BPC157 both up-regulates the VEGFR2 receptor and promotes its internalisation, with downstream VEGFR2-Akt-eNOS signalling; vessel density rose in a chick chorioallantoic membrane and in cultured human vascular endothelial cells, and blood-flow recovery accelerated in a rat hindlimb with its circulation cut off, with the effect abolished when endocytosis was blocked [4].
Note what that mechanism was demonstrated in: a bird embryo membrane, cultured endothelial cells, and a rat leg muscle. Vascular tissue, not neural tissue.
Secondary routes reported in the corpus literature include the FAK-paxillin complex, involved in cell migration; sensitisation of the growth hormone receptor in cultured tendon fibroblasts; and modulation of the nitric oxide system. The neurological strand runs through a 2016 review positioning BPC 157 as a brain-gut-axis mediator that modulates serotonergic and dopaminergic systems and engages Egr-1, NAB2, FAK-paxillin and JAK-2 signalling [7].
That review is the origin of nearly every neural claim made for this peptide online. It is a review rather than a primary experiment, it summarises rodent central-nervous-system and gastrointestinal studies, and it comes from the research group that produced most of the work it summarises.
What the research shows
The primary findings, with the species attached to each:
Tendon (rat). In a 2003 study, BPC 157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, with better collagen organisation than untreated controls, and stimulated tendocyte outgrowth in cell culture [6]. This is the single most-cited result in the compound's file and it is a rodent tendon result.
Gastric mucosa (rat). The foundational cytoprotection work reported reduced gastric ulcer area and faster ulcer healing in Wistar rats, with an ulcer-formation inhibition ratio of 45.7–65.6% at the higher doses studied and intramuscular delivery outperforming intragastric [5].
Vasculature (chick, rat, human cells). The VEGFR2 angiogenesis work described above [4].
Brain and gut signalling (rodent, review). Serotonergic and dopaminergic modulation and the intracellular pathways listed above [7].
Humans (n=2). A 2025 first-in-human intravenous safety pilot gave BPC157 at up to 20 mg to two healthy adults, a 58-year-old man and a 68-year-old woman. It was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two participants, no efficacy endpoint, no control group.
Humans (review). A 2025 narrative review concluded that despite broad preclinical support, human data are extremely limited — it counts three pilot studies in total — that rigorous large-scale trials are lacking, and that BPC-157 should be treated as investigational and approached with caution given the regulatory situation and its non-regulated availability [2].
The neural strand, and how thin it is
Set against the nerve-repair reputation, the record is short enough to state in full.
There is no study in this index in which BPC-157 was applied to an injured peripheral nerve, in any species, with an outcome measured. There is no human neural study of any kind. What exists is one review of rodent brain-gut work reporting effects on serotonin and dopamine systems and on several signalling pathways [7].
Everything else offered as neural evidence is an inference from adjacent tissue. The most common version runs: nerves need blood supply, BPC-157 promotes new blood vessels [4], therefore BPC-157 helps nerves regenerate. Each step is a real finding or a reasonable premise, and the conclusion is still unmeasured — the angiogenesis work was done in a chick membrane, a rat hindlimb and endothelial cell culture, none of which contains a regenerating axon.
A second version reasons from the FAK-paxillin migration pathway, since repair in most tissues depends on cells moving into the injury. Again: reported for this peptide in reviews of rodent work [7], not demonstrated on nerve.
The honest position is that BPC-157's neural profile is a neuropharmacology signal in rodents — changes in neurotransmitter systems — rather than a nerve-regeneration result. Those are different claims. The first is supported at the level of a single-group rodent review. The second is not supported at all.
Reported effects, cautions & safety
What people report. Everything in this subsection is anecdotal, not clinical evidence — it is what people in research-use communities describe on forums, in clinic write-ups and in commentary summarising those reports, with no controlled trial behind it and no dose attached to it here.
The most commonly described benefit is faster recovery from stubborn tendon, ligament and joint injuries — tennis elbow, rotator-cuff strains, old sprains — often within the first one to three weeks. Easier, less stiff joints are frequently mentioned alongside it. Improved digestive symptoms are also frequently reported, which people connect to the peptide's gastric origin; gastroenterologists commenting on those reports point out that no controlled human trial supports them. Less often, people describe a general sense of reduced inflammation, faster closing of minor skin wounds, or better sleep, mood and stress tolerance.
That last cluster is the one to read most carefully on this site, because it sounds neurological and is the easiest to explain another way. Commentators note it could just as well reflect sleeping better because something hurts less, a calmer gut, or plain placebo — and there is no measurement in the file that could separate those.
On the adverse side, local injection-site reactions are the most common complaint by far: brief stinging, redness or a small bump, usually described as fading within a day. Mild nausea or loose stools are frequently mentioned, more often with oral or sublingual products than injections. Occasional reports include first-week fatigue, headache, brief dizziness or lightheadedness after a dose, and transient flushing or warmth, which people link to the peptide's reported effects on blood vessels. Palpitations are rarely reported; commentators treat a persistent fast heartbeat, chest pain or marked blood-pressure change as reasons to stop and seek medical evaluation.
Documented cautions. The human evidence is extremely thin, and this is the first-order caution: animal results are not proven human benefits, and with only a handful of small uncontrolled human reports [1][2], the real balance of benefit and risk in people is genuinely unknown.
A large share of the foundational literature comes from one research group and its collaborators, so independent replication is limited — newer reviewers flag this explicitly [2]. It means a body of work that looks broad and consistent has not been widely confirmed by unrelated labs.
BPC-157 is not an approved medicine anywhere and moves through non-regulated channels, so identity, purity and actual content are unverified outside formal studies [2].
The strong pro-angiogenic activity carries a theoretical concern in cancer: tumours also depend on new blood vessels, so a strongly pro-angiogenic agent raises a mechanism-based question for anyone with an active or suspected malignancy [4]. This is reasoning from mechanism, not a finding in people.
Because rodent work shows BPC-157 altering brain serotonin activity [7], there is a mechanism-based concern about combining it with serotonin-raising medicines such as certain antidepressants. This caution is theoretical and rests on animal data; no human interaction study exists.
Cultured tendon cells showed increased growth-hormone-receptor signalling, which raises an open question about long-term effects of nudging growth pathways — unanswerable at present, since there are no long-term human safety data. BPC-157 is also prohibited in sport at all times by WADA under its non-approved-substances category, and it has not been studied in pregnancy, breastfeeding or children, where the precautionary position is avoidance.
Where BPC-157 stands on the nerve question
Counting the four substitutions from the home page: species is substituted throughout, since the efficacy record is rodent; tissue is substituted whenever tendon, ulcer or hindlimb results are read as nerve results; route and compartment are unmeasured in humans because no human pharmacokinetic dataset exists. Only molecule is not substituted — the peptide studied is the peptide discussed, which is more than can be said for TB-500.
So BPC-157 sits in an unusual position in this hub. It has the deepest preclinical file of the three and the most direct neuropharmacological evidence, and that evidence still stops well short of nerve repair. It is a rodent cytoprotection and angiogenesis compound with a rodent neurotransmitter signal attached, currently supported in humans by two people receiving an infusion without incident [1].
Anyone reading the wider internet on this compound will find that gap closed with confident language. It is not closed in the literature, and nothing on this page closes it either.